FromAstraZeneca ([email protected])
Subject (86)Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years
Preheader (149)Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial
Arial
Text Analysis
Body Words178
Subject Words12
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px832 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening
